Effects of simvastatin on cholesterol metabolism and Alzheimer disease biomarkers

Alzheimer Disease and Associated Disorders

Volumn 24, Issue 3, 2010, Pages 220-226

  Serrano Pozo, Alberto ^a,b,f   Vega, Gloria L ^d   Lütjohann, Dieter ^e   Locascio, Joseph J ^a,b   Tennis, Marsha K ^a   Deng, Amy ^a   Atri, Alireza ^a,b,c   Hyman, Bradley T ^a,b   Irizarry, Michael C ^a   Growdon, John H ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c Center for Health Quality Outcomes and Economic Research   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e UNIVERSITY OF BONN   (Germany)

^f HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

Alzheimer disease; biomarker; cholesterol; simvastatin

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN A4; BIOLOGICAL MARKER; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LATHOSTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; TAU PROTEIN; TRIACYLGLYCEROL;

AGED; ALZHEIMER DISEASE; AMNESIA; ARTICLE; CHOLESTEROL METABOLISM; CLINICAL ARTICLE; DRUG DOSE INCREASE; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MALE; METABOLITE; MILD COGNITIVE IMPAIRMENT; OPEN STUDY; PATIENT COMPLIANCE; PLASMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; TREATMENT OUTCOME;

EID: 77956411745     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: 10.1097/WAD.0b013e3181d61fea     Document Type: Article

References (61)

1. Hirtz D, Thurman D, Gwinn-Hardy K, et al. How common are the "common" neurologic disorders? Neurology. 2007;68: 326-337. (Pubitemid 46188246)
2. Hebert LE, Scherr PA, Bienias JL, et al. Alzheimer disease in the US population. Prevalence estimates using the 2000 census. Arch Neurol. 2003;60:1119-1122.
3. Pappolla MA, Bryant-Thomas TK, Herbert D, et al. Mild hypercholesterolemia is an early risk factor for the development of Alzheimer amyloid pathology. Neurology. 2003;61: 199-205.
4. Solomon A, Kareholt I, Ngandu T, et al. Serum cholesterol changes after midlife and late-life cognition: twenty-one-year follow-up study. Neurology. 2007;68:751-756.
5. Refolo LM, Pappolla MA, Malester B, et al. Hypercholesterolemia accelerates the Alzheimer s amyloid pathology in a transgenic mouse model. Neurobiol Dis. 2000;7:321-331.
6. Refolo LM, Pappolla MA, LaFrancois J, et al. A cholesterollowering drug reduces b-amyloid pathology in a transgenic mouse model of Alzheimer s disease. Neurobiol Dis. 2001;8: 890-899.
7. Kojro E GG, Lammich S, März W, et al. Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the a-secretase ADAM10. Proc Nat Acad Sci. 2001;98:5815-5820.
8. Fassbender K, Simons M, Bergmann C, et al. Simvastatin strongly reduces levels of Alzheimer s disease b-amyloid peptides Ab42 and Ab40 in vitro and in vivo. Proc Nat Acad Sci. 2001;98:5856-5861.
9. Parvathy S, Ehrlich M, Pedrini S, et al. Atorvastatin-induced activation of Alzheimer s a secretase is resistant to standard inhibitors of protein phosphorylation-regulated ectodomain shedding. J Neurochem. 2004;90:1005-1010.
10. Cordle A, Koenigsknecht-Talboo J, Wilkinson B, et al. Mechanisms of statin-mediated inhibition of small G-protein function. J Biol Chem. 2005;280:34202-34209.
11. Cordle A, Landreth G. 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors attenuate b-amyloid-induced microglial inflammatory responses. J Neurosci. 2005;25:299-307.
12. Bi X, Baudry M, Liu J, et al. Inhibition of geranylgenarylation mediates the effects of 3-hydroxy-3-methylglutaryl (HMG)- CoA reductase inhibitors on microglia. J Biol Chem. 2004;279: 48238-48245.
13. Cole SL, Grudzien A,Manhart IO, et al. Statins cause intracellular accumulation of amyloid precursor protein, b-secretase-cleaved fragments, and amyloid b-peptide via an isoprenoid-dependent mechanism. J Biol Chem. 2005;280:18755-18770.
14. Ostrowski SM, Wilkinson BL, Golde TE, et al. Statins reduce amyloid-b production through inhibition of protein isoprenylation. J Biol Chem. 2007;282:26832-26844.
15. Li L, Cao D, Kim H, et al. Simvastatin enhances learning and memory independent of amyloid load in mice. Ann Neurol. 2006;60:729-739.
16. Wolozin B, KellmanW, Ruosseau P, et al. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arch Neurol. 2000;57: 1439-1443.
17. Jick H, Zornberg GL, Jick SS, et al. Statins and the risk of dementia. Lancet. 2000;356:1627-1631.
18. Rodriguez EG, Dodge HH, Birzescu MA, et al. Use of lipidlowering drugs in older adults with and without dementia: a community-based epidemiological study. J Am Geriatr Soc. 2002;50:1852-1856.
19. Hajjar I, Schumpert J, Hirth V, et al. The impact of the use of statins on the prevalence of dementia and the progression of cognitive impairment. J Gerontol Med Sci. 2002;57A: M414-M418.
20. Rockwood K, Kirkland S, Hogan DB, et al. Use of lipidlowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch Neurol. 2002;59: 223-227.
21. Zamrini E, McGwin G, Roseman JM. Association between statin use and Alzheimer s disease. Neuroepidemiology. 2004; 23:94-98.
22. Dufuoil C, Richard F, Fiévet N, et al. APOE genotype, cholesterol level, lipid-lowering treatment, and dementia. The Three- City Study. Neurology. 2005;64:1531-1538.
23. Li G, Higdon R, Kukull WA, et al. Statin therapy and risk of dementia in the elderly. A community-based prospective cohort study. Neurology. 2004;63:1624-1628.
24. Rea TD, Breitner JC, Psaty BM, et al. Statin use and the risk of incident dementia. The Cardiovascular Health Study. Arch Neurol. 2005;62:1047-1051.
25. Zandi PP, Sparks DL, Kachaturian AS, et al. Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study. Arch Gen Psychiatry. 2005;62:217-224.
26. Arvanitakis Z, Schneider JA, Wilson RS, et al. Statins, incident Alzheimer disease, change in cognitive function, and neuropathology. Neurology. 2008;70:1795-1802.
27. Zhou B, Teramukai S, Fukushima M. Prevention and treatment of dementia or Alzheimer s disease by statins: a metaanalysis. Dement Geriatr Cogn Disord. 2007;23:194-201.
28. Yaffe K, Barrett-Connor E, Lin F, et al. Serum lipoproteins levels, statin use, and cognitive function in older women. Arch Neurol. 2002;59:378-384.
29. Cramer C, Haan MN, Galea S, et al. Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study. Neurology. 2008;71:344-350.
30. Haag MDM, Hofman A, Koudstaal PJ, et al. Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study. J Neurol Neurosurg Psychiatr. 2009;80:13-17.
31. Li G, Larson EB, Sonnen JA, et al. Statin therapy is associated with reduced neuropathologic changes of Alzheimer disease. Neurology. 2007;69:878-885.
32. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebocontrolled trial. Lancet. 2002;360:7-22.
33. Sheperd J, Blauw GJ, Murphy MB, et al, on behalf of the PROSPER study group. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360:1623-1630.
34. Sparks DL, Sabbagh MN, Connor DJ, et al. Atorvastatin for the treatment of mild to moderate Alzheimer disease. Preliminary results. Arch Neurol. 2005;62:753-757.
35. Sparks DL, Connor DJ, Sabbagh MN, et al. Circulating cholesterol levels, apolipoprotein E genotype, and dementia severity influence the benefit of atorvastatin treatment in Alzheimer s disease: results of the Alzheimer s Disease Cholesterol-Lowering Treatment (ADCTL) Trial. Acta Neurol Scand. 2006;114(suppl 185):3-7.
36. Masse I, Bordet R, Deplanque D, et al. Lipid lowering agents are associated with a lower cognitive decline in Alzheimer s disease. J Neurol Neurosurg Psychiatr. 2005;76:1624-1629.
37. Ellul J, Archer N, Foy CML, et al. The effects of commonly prescribed drugs in patients with Alzheimer s disease on the rate of deterioration. J Neurol Neurosurg Psychiatr. 2007;78: 233-239.
38. Vega GL, Weiner MF, Lipton AM, et al. Reduction in levels of 24S-hydroxycholesterol by statin treatment in patients with Alzheimer Disease. Arch Neurol. 2003;60:510-515.
39. Tokuda T, Tamaoka A, Matsuno S, et al. Plasma levels of amyloid b proteins did not differ between subjects taking statins and those not taking statins. Ann Neurol. 2001;49: 546-547.
40. Simons M, Schwärzler F, Lütjohann D, et al. Treatment with simvastatin in normocholesterolemic patients with Alzheimer s disease: a 26-week randomized, placebo-controlled, doubleblind trial. Ann Neurol. 2002;52:346-350.
41. Fassbender K, Stroick M, Bertsch T, et al. Effects of simvastatin on human cerebral cholesterol metabolism and secretion of Alzheimer amyloid peptide. Neurology. 2002;59: 1257-1258.
42. Ishii K, Tokuda T, Matsushima T, et al. Pravastatin at 10 mg/ day does not decrease plasma levels of either amyloid-b (Ab) 40 or Ab 42 in humans. Neurosci Lett. 2003;350:161-164.
43. Sjögren M, Gustafsson K, Syversen S, et al. Treatment with simvastatin in patients with Alzheimer s disease lowers both a- and b-cleaved amyloid precursor protein. Dement Geriatr Cogn Disord. 2003;16:25-30.
44. Höglund K, Wiklund O, Vanderstichele H, et al Plasma levels of b-amyloid(1-40), b-amyloid(1-42), and total b-amyloid remain unaffected in adult patients with hypercholesterolemia after treatment with statins. Arch Neurol. 2004; 61 333-337.
45. Höglund K, Thelen KM, Syversen S, et al. The effect of simvastatin treatment on the amyloid precursor protein and brain cholesterol metabolism in patients with Alzheimer s disease. Dement Geriatr Cogn Disord. 2005;19:256-265.
46. Höglund K, Syversen S, Lewezuk P, et al. Statin treatment and a disease specific pattern of b-amyloid peptides in Alzheimer s disease. Exp Brain Res. 2005;164:205-214.
47. Hinerfeld DA, Moonis M, Swearer JM, et al. Statins differentially affect amyloid precursor protein metabolism in presymptomatic PS1 and non-PS1 subjects. Arch Neurol. 2007;64: 1672-1673.
48. Carlsson CM, Gleason CE, Hess TM, et al. Effects of simvastatin on cerebrospinal fluid biomarkers and cognition in middleaged adults at risk for Alzheimer s disease. J Alzh Dis. 2008;13: 187-197.
49. Locatelli S, Lütjohann D, Schmidt HHJ, et al. Reduction of plasma 24S-hydroxycholesterol (cerebrosterol) levels using high-dosage simvastatin in patients with hypercholesterolemia. Evidence that simvastatin affects cholesterol metabolism in the human brain. Arch Neurol. 2002;59:213-216.
50. Vega GL, Weiner MF. Plasma 24S hydroxycholesterol response to statins in Alzheimer s disease patients: effects of gender, CYP46, and ApoE polymorphisms. J Mol Neurosci. 2007; 33:51-55.
51. Riekse RG, Li G, Petrie EC, et al. Effect of statins on Alzheimer s disease biomarkers in cerebrospinal fluid. J Alzh Dis. 2006;10:399-406.
52. Friedhoff LT, Cullen EI, Geoghagen NS, et al. Treatment with controlled-released lovastatin decreases serum concentrations of human b-amyloid (Ab) peptide. Int J Neuropsychopharmacol. 2001;4:127-130.
53. Lennernas H, Fager G. Pharmacodynamics and pharmacokinetics of HMGCoA reductase inhibitors. Similarities and differences. Clin Pharmacokinet. 1997;32:403-425.
54. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer s Disease. Neurology. 1984;34:939-944.
55. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004;256:183-194.
56. Morris JC. The clinical dementia rating (CDR): current version and scoring rules. Neurology. 1993;43:2412-2414.
57. Bateman RJ, Wen G, Morris JC, et al. Fluctuations of CSF amyloid-b levels. Implications for a diagnostic and therapeutic biomarker. Neurology. 2007;68:666-669.
58. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189-198.
59. Blessed G, Tomlinson B, Roth M. The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br J Psychiatr. 1968; 114:797-811.
60. Lütjohann D. Cholesterol metabolism in the brain: importance of 24S-hydroxylation. Acta Neurol Scand. 2006;185(suppl):33-42.
61. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.